These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 2942707

  • 1. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R.
    J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.
    de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S.
    J Urol; 1986 Feb; 135(2):303-7. PubMed ID: 2935644
    [Abstract] [Full Text] [Related]

  • 3. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
    Pavone-Macaluso M, Schröder FH, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R, Smith PH, Suciu S.
    Prog Clin Biol Res; 1989 Feb; 303():111-6. PubMed ID: 2528735
    [No Abstract] [Full Text] [Related]

  • 4. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ, Pavone-Macaluso M, Smith PH, de Pauw M, Suciu S.
    Prog Clin Biol Res; 1988 Feb; 260():111-7. PubMed ID: 2966403
    [No Abstract] [Full Text] [Related]

  • 5. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
    Pavone-Macaluso M, Martínez-Piñeiro JA, de Voogt H, Lardennois B, Nasta A, Zolfanelli R, Barasolo E, De Pauw M, Suciu S, Sulvester R.
    Arch Esp Urol; 1982 Feb; 35(5):304-11. PubMed ID: 6217788
    [No Abstract] [Full Text] [Related]

  • 6. Re: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer Trials 30761 and 30762.
    deVoogt HJ, Pavone-Macaluso M, Sylvester R, Schröder FH.
    J Urol; 1988 Dec; 140(6):1557. PubMed ID: 2973530
    [No Abstract] [Full Text] [Related]

  • 7. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
    Pavone-Macaluso M, Ingargiola GB, de Voogt H, Viggiano G, Barasolo E, Lardennois B, De Pauw M, Sylvester R.
    Prog Clin Biol Res; 1987 Dec; 243A():379-82. PubMed ID: 2958862
    [No Abstract] [Full Text] [Related]

  • 8. Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials.
    de Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH, de Pauw M.
    J Urol; 1989 Apr; 141(4):883-8. PubMed ID: 2522561
    [Abstract] [Full Text] [Related]

  • 9. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
    Smith PH, Suciu S, Robinson MR, Richards B, Bastable JR, Glashan RW, Bouffioux C, Lardennois B, Williams RE, de Pauw M.
    J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
    [Abstract] [Full Text] [Related]

  • 10. Treatment of prostatic cancer: the EORTC experience--preliminary results of prostatic carcinoma trials.
    Schroeder FH.
    Prostate; 1984 Sep; 5(2):193-8. PubMed ID: 6231535
    [Abstract] [Full Text] [Related]

  • 11. Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study.
    Bollack C, Rougeron G.
    Am J Clin Oncol; 1988 Sep; 11 Suppl 2():S156-9. PubMed ID: 2977270
    [Abstract] [Full Text] [Related]

  • 12. Hormonal therapy of advanced prostatic cancer.
    Fair WR.
    J Urol; 1986 Sep; 136(3):653-4. PubMed ID: 2942708
    [No Abstract] [Full Text] [Related]

  • 13. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM.
    Am J Clin Oncol; 1988 Sep; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.
    Moffat LE.
    Eur Urol; 1990 Sep; 18 Suppl 3():26-7. PubMed ID: 2151272
    [No Abstract] [Full Text] [Related]

  • 15. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
    Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM.
    J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
    [Abstract] [Full Text] [Related]

  • 16. Is there a best endocrine management of prostatic carcinoma?
    Robinson MR.
    Prog Clin Biol Res; 1988 Dec; 269():147-58. PubMed ID: 2969114
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
    Irani J, Salomon L, Oba R, Bouchard P, Mottet N.
    Lancet Oncol; 2010 Feb; 11(2):147-54. PubMed ID: 19963436
    [Abstract] [Full Text] [Related]

  • 18. EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate.
    Robinson MR.
    Prog Clin Biol Res; 1988 Feb; 260():101-10. PubMed ID: 2966402
    [No Abstract] [Full Text] [Related]

  • 19. EORTC protocols in prostatic cancer. An interim report.
    Pavone-Macaluso M, Lund F, Mulder JH, Smith PH, De Pauw M, Sylvester R.
    Scand J Urol Nephrol Suppl; 1980 Feb; 55():163-8. PubMed ID: 6938020
    [Abstract] [Full Text] [Related]

  • 20. Treatment of advanced prostatic carcinoma with cyproterone acetate and orchiectomy--5-year follow-up.
    Giuliani L, Pescatore D, Giberti C, Martorana G, Natta G.
    Eur Urol; 1980 Feb; 6(3):145-8. PubMed ID: 7371659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.